Supplementary Figure S1

A



B



C IC50 of erlotinib in four HNSCC cells

Cell line	Organ	Histology	IC50 (μM)
JHU-011	Larynx	HNSCC	0.27
JHU-013	neck node	HNSCC	7.9
JHU-022	Larynx	HNSCC	0.23
JHU-029	Tongue	HNSCC	43

Figure S1 Sensitivity of HNSCC cells to erlotinib (μM). (A) Dose-escalation effects of erlotinib on cell viability in the JHU-022 HNSCC cells. The cells were exposed to vehicle or erlotinib with increased doses for 7 days. Data are shown of two duplicates. (B, C) IC50 of JHU-011,
-013, -022 and -029 cells to erlotinib. Data of four independent experiments are presented as mean ± SEM (n= 4).

Supplementary Figure S2

A



B



C

IC50 of cetuximab in four HNSCC cells

Cell line	Organ	Histology	IC50 (µg/mL)
JHU-011	Larynx	HNSCC	35.2
JHU-013	neck node	HNSCC	50.5
JHU-022	Larynx	HNSCC	101.4
JHU-029	Tongue	HNSCC	103.3

Figure S2 Sensitivity of HNSCC cells to cetuximab (µg/mL). (A) Dose-escalation effects of cetuximab on cell viability in the JHU-029 HNSCC cells. The cells were exposed to vehicle or cetuximab with increased doses for 7 days. Data are shown of two duplicates. (B, C) IC50 of JHU-011, -013, -022 and -029 cells to cetuximab. Data of four independent experiments are presented as mean ± SEM (n= 4).